Esophagus to Small Intestine

Am J Gastroenterol. 2024;119(4):635–45

Low EE, Demb J, Shah SC, Liu L, Bustamante R, Yadlapati R, Gupta S

Risk of esophageal cancer in achalasia: A matched cohort study using the nationwide Veterans Affairs Achalasia Cohort


Introduction: Achalasia is a postulated risk factor of esophageal cancer (EC); however, EC-associated risk in achalasia is understudied. The authors aimed to evaluate EC risk among individuals within the nationwide Veterans Affairs Achalasia Cohort.
Methods: They conducted a matched cohort study among US veterans aged 18 years or older from 1999 to 2019. Individuals with achalasia were age matched and sex matched 1:4 to individuals without achalasia. Follow-up continued from study entry until diagnosis with incident/fatal EC (primary outcome), death from non-EC-related causes, or end of the study follow-up (December 31, 2019). Association between achalasia and EC risk was examined using Cox regression models.
Results: 9315 individuals were included in the analytic cohort (median age, 55 years; 92% male): 1863 with achalasia matched to 7452 without achalasia. During a median 5.5 years of follow-up, 17 EC occurred (3 esophageal adenocarcinoma, 12 squamous cell carcinoma, and 2 unknown type) among individuals with achalasia, compared with 15 EC (11 esophageal adenocarcinoma, 1 squamous cell carcinoma, and 3 unknown type) among those without achalasia. EC incidence for those with achalasia was 1.4 per 1000 person-years, and the median time from achalasia diagnosis to EC development was 3.0 years (Q1–Q3: 1.3–9.1). Individuals with achalasia had higher cumulative EC incidence at 5, 10, and 15 years of follow-up compared with individuals without achalasia, and EC risk was 5-fold higher (hazard ratio = 4.6, 95% confidence interval: 2.3–9.2).

Discussion: Based on substantial esophageal cancer (EC) risk, individuals with achalasia may benefit from a high index of suspicion and endoscopic surveillance for EC.

S. Gupta, Jennifer Moreno Veteran Affairs San Diego Healthcare System, San Diego, CA, USA, E-Mail: s1gupta@health.ucsd.edu

DOI: 10.14309/ajg.0000000000002591

Back to overview

this could be of interest:

Standard of care versus octreotide in angiodysplasia-related bleeding (the OCEAN study): A multicenter randomized controlled trial

Gastroenterology. 2024;166(4):690–703

Early initiation of biologics and disease outcomes in adults and children with inflammatory bowel diseases: Results from the epidemiology group of the nationwide Israeli Inflammatory Bowel Disease Research Nucleus cohort

Gastroenterology. 2024;166(5):815–25.e22

More articles on the topic